false 0001022899 0001022899 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported):   November 17, 2026

 

PROTAGENIC THERAPEUTICS, INC.  

 

(Exact name of Company as specified in its charter)

 

Delaware   001-12555   06-1390025

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

149 Fifth Avenue, Suite 500, New York, NY   10010
(Address of principal executive offices)   (Zip Code)

 

212-994-8200

 

(Company’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
         

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On November 10, 2026, Protagenic Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”). Under the Purchase Agreement, the Company agreed to issue and sell to the Purchasers, in a private placement offering (the “Private Placement”), the following securities at the Initial Closing (as defined below): (i) 2,459,014 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”); (ii) Series A common stock purchase warrants to purchase up to 2,459,014 shares of Common Stock (the “Series A Warrants”); and (iii) Series B common stock purchase warrants to purchase up to 2,459,014 shares of Common Stock (the “Series B Warrants” and, together with the Series A Warrants, the “Common Warrants”).

 

The purchase price was $0.61 per share of Common Stock and accompanying Common Warrants. This price equals 90% of the volume weighted average price of the Common Stock for the 30 consecutive trading days ending on the trading day immediately preceding the date of the Purchase Agreement. The Purchasers’ subscription amounts were deposited with Odyssey Transfer and Trust Company, as escrow agent, under an escrow agreement dated as of September 25, 2026. Under the Purchase Agreement, the purchase price per Pre-Funded Warrant and accompanying Common Warrants is equal to the per-share purchase price minus $0.0001.

 

The initial closing of the Private Placement occurred on November 17, 2026 (the “Initial Closing”). At the Initial Closing, the Company received gross proceeds of approximately $1.5 million, before deducting placement agent fees and other offering expenses.

 

Under the Purchase Agreement, the Company may sell additional securities on the same terms at one or more subsequent closings until the earlier of (i) December 31, 2026 and (ii) the date on which the maximum offering amount has been sold. The maximum offering amount is $3,000,000, which the Company may increase in its discretion to up to $5,000,000.

 

Pre-Funded Warrants. Under the Purchase Agreement, any Purchaser whose purchase of shares of Common Stock in the Private Placement would otherwise result in that Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the Purchaser’s election, 9.99%) of the Company’s outstanding Common Stock immediately following the applicable closing may elect to purchase pre-funded warrants to purchase shares of Common Stock (the “Pre-Funded Warrants”) in lieu of shares of Common Stock. The Pre-Funded Warrants, if any, have an exercise price of $0.0001 per share, are immediately exercisable and remain exercisable until exercised in full. No Pre-Funded Warrants were issued at the Initial Closing.

 

Common Warrants. The Common Warrants are exercisable for cash only, beginning immediately upon issuance. The Series A Warrants have an exercise price of $0.67 per share, equal to 110% of the per-share purchase price. The Series B Warrants have an exercise price of $0.73 per share, equal to 120% of the per-share purchase price.

 

Each Common Warrant expires at 5:00 p.m. (New York City time) on the earliest of:

 

  (i) the fifth anniversary of its issuance date;
     
  (ii) the 30th day following the last day of any period of 10 consecutive trading days during which the volume weighted average price of the Common Stock equals or exceeds 200% of the per-share purchase price; and
     
  (iii) the 30th day following the Company’s public disclosure of the dosing of the tenth patient in its planned Phase 1/2a clinical trial of PT00114 in Generalized Anxiety Disorder.

 

Beneficial ownership limitation. A holder of a Common Warrant or Pre-Funded Warrant may not exercise any portion of the warrant if the holder, together with its affiliates, would then beneficially own more than 4.99% (or, at the holder’s election, 9.99%) of the shares of Common Stock outstanding immediately after giving effect to the exercise.

 

 

 

 

Covenants. The Purchase Agreement contains customary representations, warranties and covenants of the Company and the Purchasers, and customary indemnification obligations. Under the Purchase Agreement, the Company has agreed not to issue or agree to issue shares of Common Stock or Common Stock equivalents, subject to certain exceptions, from the date of the Purchase Agreement until 45 days after the Effective Date (as defined in the Purchase Agreement). The Company has also agreed not to enter into any variable rate transaction until the first anniversary of the Effective Date.

 

Use of proceeds. The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including product development, clinical programs and operating expenses.

 

Placement agent. Brookline Capital Markets, a division of Arcadia Securities, LLC (the “Placement Agent”), acted as placement agent for the Private Placement under a placement agency agreement dated as of June 19, 2026 (the “Placement Agency Agreement”). Under the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds of the Private Placement, payable at each closing from the escrow account, and a non-accountable expense allowance equal to 1.0% of the aggregate gross proceeds of the Private Placement, and to reimburse the Placement Agent for certain of its reasonable and documented out-of-pocket expenses, up to $75,000 without the Company’s prior written approval. The Company also agreed to issue to the Placement Agent, a number of Placement Agent Warrants equivalent to 7.0% of the total number of Common Warrants issued to investors in the Private Placement (the “Placement Agent Warrants”). The Company also agreed to indemnify the Placement Agent against certain liabilities. Pursuant to the Placement Agency Agreement, the Company’s directors, executive officers, employees and certain shareholders entered into “lock-up” agreements pursuant to which they have agreed, subject to certain exceptions, not to sell or transfer any securities of the Company that they hold for a period of ninety (90) days from the final closing of the Private Placement.

 

Registration rights. In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchasers (the “Registration Rights Agreement”). Under the Registration Rights Agreement, the Company agreed to file one or more registration statements with the Securities and Exchange Commission (the “SEC”) to register the resale of the shares of Common Stock sold in the Private Placement and the shares issuable upon exercise of the Pre-Funded Warrants and Common Warrants. The Company agreed to file within 45 days and to use commercially reasonable efforts to have the registration statement declared effective within 90 days (or 150 days in the event of a “full review” by the SEC). The Company is subject to liquidated damages if it fails to meet these deadlines.

 

Exempt offering. None of the securities sold in the Private Placement, the Placement Agent Warrants, or the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the Common Warrants and the Placement Agent Warrants, have been registered under the Securities Act of 1933, as amended (the “Securities Act”). These securities were offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.

 

The Purchase Agreement is filed as an exhibit to this Current Report on Form 8-K to provide investors and stockholders with information regarding its terms. It is not intended to provide any other factual information about the Company or the Purchasers. The representations, warranties and covenants in the Purchase Agreement were made solely for the purposes of that agreement and as of specific dates, and solely for the benefit of the parties to it. They may be subject to limitations agreed upon by the contracting parties, may have been made to allocate contractual risk among the parties rather than to establish matters as facts, and may be subject to standards of materiality that differ from those applicable to investors. Investors are not third-party beneficiaries under the Purchase Agreement and should not rely on the representations, warranties and covenants as characterizations of the actual state of facts or condition of the Company.

 

The foregoing descriptions of the Purchase Agreement, the Registration Rights Agreement, the Pre-Funded Warrants,, the Series A Warrants, the Series B Warrants and the Placement Agent Warrants are not complete. Each is qualified in its entirety by reference to the full text of the applicable document (or form), filed as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5 and 10.6, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

 

 

 

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. Based in part on the representations of the Purchasers in the Purchase Agreement, the offer and sale of the securities in the Private Placement is exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and under corresponding provisions of state securities or “blue sky” laws. Each Purchaser represented that it is an accredited investor and is acquiring the securities for its own account and not with a view to distribution. The securities were offered without any general solicitation by the Company or its representatives.

 

Item 7.01 Regulation FD Disclosure.

 

On November 11, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference into this Item 7.01. The information contained in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except to the extent expressly stated in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are being filed herewith:

 

Exhibit No.   Description
10.1   Form of Securities Purchase Agreement
10.2   Form of Registration Rights Agreement
10.3   Form of Pre-funded Warrant
10.4   Form of Series A Warrant
10.5   Form of Series B Warrant
10.6   Form of Placement Agent Warrant
99.1   Press Release dated November 11, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTAGENIC THERAPEUTICS, INC.
     
Date: November 17, 2026 By: /s/ Bill Nichols
  Name: Bill Nichols
  Title: President